Clinically, typical HUS presents with a classic prodrome of several days of watery diarrhea followed by bloody diarrhea (dysentery). Approximately five to ten days after the onset of diarrhea, the triad of HUS manifests: pallor (anemia), petechiae and bruising (thrombocytopenia), and decreased urine output (acute kidney injury). The prognosis for typical HUS is surprisingly favorable. With aggressive supportive care—including meticulous fluid and electrolyte management, blood transfusions, and often dialysis—the majority of children recover renal function completely. The mortality rate is low (1-5%) in the acute phase, and long-term sequelae, such as chronic kidney disease or hypertension, occur in a minority of patients. Crucially, typical HUS is not a recurrent disease; once a patient recovers from the acute infection, the syndrome does not return.
Hemolytic uremic syndrome (HUS) is a clinical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. While this definition is clear, the syndrome is not a single disease but rather a spectrum of conditions with vastly different etiologies, treatments, and prognoses. The critical distinction lies between typical HUS, also known as Shiga toxin-producing E. coli HUS (STEC-HUS), and atypical HUS (aHUS). Although they share a common final pathway of endothelial damage and microvascular thrombosis, their underlying mechanisms, clinical triggers, and long-term outcomes diverge so significantly that they are best understood as two distinct disorders: one an acute, often self-limited infection, the other a chronic, life-threatening genetic disease of complement dysregulation. typical vs atypical hemolytic uremic syndrome
While aHUS can be triggered by an environmental insult (e.g., infection, pregnancy, surgery, certain medications), the fundamental problem is an intrinsic failure to regulate the complement cascade. This leads to systemic, recurrent, and progressive thrombotic microangiopathy, with a predilection for the kidneys but often affecting other organs such as the brain, heart, and gastrointestinal tract. The clinical presentation is variable and can lack the diarrheal prodrome typical of STEC-HUS. The prognosis for aHUS before the modern era was grim, with up to 50% of patients progressing to end-stage renal disease (ESRD) or death within the first year of diagnosis. Furthermore, aHUS is characterized by a high rate of recurrence, especially after kidney transplantation—indeed, the disease frequently destroys the transplanted organ unless the underlying complement dysregulation is addressed. Clinically, typical HUS presents with a classic prodrome
For aHUS, supportive care is insufficient. The therapeutic cornerstone is the blockade of terminal complement activation. The advent of eculizumab, a monoclonal antibody that inhibits the complement protein C5, has revolutionized the treatment of aHUS. This drug rapidly halts the thrombotic process, improves renal function, and prevents recurrence, including after transplantation. Without eculizumab or similar complement inhibitors, patients with aHUS face a lifetime of recurrent thrombotic crises and progressive organ failure. Hemolytic uremic syndrome (HUS) is a clinical triad